专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050026833A1 PSP-94: use for treatment of hypercalcemia and bone metastasis 审中-公开
标题翻译： PSP-94：用于治疗高钙血症和骨转移
公开(公告)号：US20050026833A1
公开(公告)日：2005-02-03
申请号：US10857358
申请日：2004-06-01
申请人： Shafaat Rabbani , Nicholas Shukeir , Chandra Panchal , Christopher Newman
发明人： Shafaat Rabbani , Nicholas Shukeir , Chandra Panchal , Christopher Newman
IPC分类号： A61K38/17 , C07K14/47 , G01N33/574 , G01N33/84
CPC分类号： C07K14/47 , A61K38/1709 , G01N33/57434 , G01N33/84 , G01N2333/635 , G01N2500/00
摘要： The present invention discloses the use of PSP-94, PCK3145 and other derivatives and biologically active analogues for treating a patient having a condition such as metastasis, metastatic cancer, a condition associated with elevated levels of parathyroid hormone-related protein (PTHrP), PTHrP-induced osteolysis and/or hypercalcemia of malignancy. These compounds were found to be effective treatment modalities for bone metastasis caused by prostate cancer. Furthermore, decrease in cellular and plasma PTHrP levels as well as plasma calcium levels observed by treatment with such compound can serve as useful biochemical markers for monitoring the efficacy of these anti-metastatic compounds.
摘要翻译：本发明公开了使用PSP-94，PCK3145等衍生物和生物活性类似物治疗患有转移，转移性癌症的病人，与甲状旁腺激素相关蛋白（PTHrP）水平升高相关的病症，PTHrP 诱发的骨质溶解和/或恶化的高钙血症。发现这些化合物是由前列腺癌引起的骨转移的有效治疗方式。此外，通过用这种化合物治疗观察到的细胞和血浆PTHrP水平以及血浆钙水平的降低可以作为监测这些抗转移化合物的功效的有用的生物化学标记物。

2. 发明申请

US20070190068A1 uPAR-binding molecule-drug conjugates and uses thereof 审中-公开
标题翻译： uPAR结合分子 - 药物共轭物及其用途
公开(公告)号：US20070190068A1
公开(公告)日：2007-08-16
申请号：US11546582
申请日：2006-10-10
申请人： Richard Hart , Shafaat Rabbani
发明人： Richard Hart , Shafaat Rabbani
IPC分类号： A61K39/395
CPC分类号： A61K47/6849
摘要： The present invention relates to the use of uPAR-binding molecule-drug conjugates capable of specifically binding a urokinase plasminogen activator receptor (uPAR) as therapeutic and diagnostic reagents for the treatment and monitoring of metastases. The present invention provides methods of treatment of metastases, comprising administering to a subject a uPAR-binding molecule-chemotherapeutic conjugate that is capable of binding to and internalizing into uPAR-expressing cells. The present invention further provides pharmaceutical compositions and kits comprising such conjugates. The present invention further provides methods and compositions relating to combination therapy for cancer involving or mediated by uPAR-expressing cells using uPAR-binding molecule-drug conjugates of the invention.
摘要翻译：本发明涉及能够特异性结合尿激酶纤溶酶原激活物受体（uPAR）的uPAR结合分子 - 药物偶联物作为用于治疗和监测转移的治疗和诊断试剂的用途。本发明提供治疗转移的方法，包括向受试者施用能够结合并内化成uPAR表达细胞的uPAR结合分子 - 化疗缀合物。本发明还提供了包含这种缀合物的药物组合物和试剂盒。本发明还提供了涉及使用本发明的uPAR结合分子 - 药物偶联物的涉及uPAR表达细胞的癌症的组合疗法的方法和组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式